Clinical Trial Update: A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase III, multicenter randomized open-label trial is evaluating a PD-1 inhibitor with anti-vascular therapy and anthracycline/taxane-based adjuvant chemother…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)
• PD-1 inhibitor

Snippet

Sponsor: Fudan University | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 3 | Status: RECRUITING